AP-22408 is an inhibitor of SRC tyrosine kinase.

ERCC1-XPF-IN-2 is active in nucleotide excision repair, cisplatin enhancement and γH2AX assays. ERCC1-XPF-IN-2 is a potent inhibitor of ERCC1-XPF endonuclease with an IC 50 value of 0.6 μM [1].

MCC1189 is a first-in-class MFS efflux pump CaMdr1p inhibitor.

MCC1019 is a novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1).

ACC1/2-IN-2 (compound PF-3) is a potent inhibitor of ACC1/2 with IC50s of 22 and 48 nM for ACC1 and ACC2, respectively. ACC1/2-IN-2 shows antiproliferation activity and has research value in cancer research.

ACC1/2-IN-1 is a potent inhibitor of ACC1/2 and acts on ACC1 (IC50: 98.06 nM) and ACC2 (IC50: 29.43 nM). ACC1/2-IN-1 can be used in cancer research.

ERCC1-XPF-IN-1 is a potent, high-affinity inhibitor of ERCC1-XPF (IC50: 0.49 μM). ERCC1-XPF-IN-1 inhibits the removal of CPDs, reduces the toxicity of cyclophosphamide to colorectal cancer cells, enhances the cytotoxic effects of UV radiation, and impedes DNA repair.